Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress
Salarius Pharmaceuticals (Nasdaq: SLRX) announced a conference call scheduled for May 12, 2022, at 5:00 p.m. ET to discuss its financial results for the first quarter of 2022. Interested participants can join via phone or listen to the live webcast on the company's investor relations website. Salarius is focused on developing innovative cancer therapies, including seclidemstat, which is in clinical trials for conditions such as Ewing sarcoma. The product has received multiple designations from the FDA, emphasizing its potential in treating unmet medical needs.
- Seclidemstat received Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation from the FDA for Ewing sarcoma.
- Seclidemstat is currently in Phase 1/2 clinical trials for relapsed/refractory Ewing sarcoma and related cancers.
- Salarius received financial support from the National Pediatric Cancer Foundation for its clinical program.
- None.
Conference Call and Live Audio Webcast Scheduled for Thursday, May 12, 2022, 5:00 p.m. ET
HOUSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that the Company will host a conference call and live audio webcast on Thursday, May 12, 2022, at 5:00 p.m. ET, to discuss its corporate and financial results for the three months ended March 31, 2022.
Conference Call Information:
Interested participants and investors may access the conference call by dialing either:
- (833) 423-0481 (U.S.)
- (918) 922-2375 (International)
- Conference ID: 8798303
An audio webcast will be accessible via the Investors Events and Presentations section of the Company’s website http://investors.salariuspharma.com/. An archive of the webcast will remain available for 90 days beginning at approximately 6:00 p.m. ET, on May 12, 2022.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius’ product portfolio includes seclidemstat, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and select additional sarcomas that share a similar biology to Ewing sarcoma, also referred to as Ewing-related or FET-rearranged sarcomas. Seclidemstat has received Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation for Ewing sarcoma from the U.S. Food and Drug Administration. Salarius is also exploring seclidemstat’s potential in several cancers with high unmet medical need, with a second Phase 1/2 clinical study in hematologic cancers, initiated by MD Anderson Cancer Center. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com or follow Salarius on Twitter and LinkedIn.
Contact
Tiberend Strategic Advisors, Inc.
Investor Relations
Daniel Kontoh-Boateng
dboateng@tiberend.com
Media Relations
Jason Rando
jrando@tiberend.com
FAQ
What is the date of the Salarius Pharmaceuticals conference call?
How can I access the Salarius Pharmaceuticals conference call?
What are the focuses of Salarius Pharmaceuticals' clinical trials?
What designations has seclidemstat received from the FDA?
What financial support has Salarius Pharmaceuticals received?
